A Phase 1/2 Study of IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 22 May 2025
At a glance
- Drugs IBI 3014 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Innovent Biologics
Most Recent Events
- 22 May 2025 New trial record